Ponatinib in refractory Philadelphia chromosome-positive leukemias.
about
Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home settingPotential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemiaChronic myeloid leukemia: reminiscences and dreamsEuropean LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaManagement of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors TreatmentEmerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future DirectionsKinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsClinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerationsResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsCIViC databaseAcquired Resistance to Crizotinib from a Mutation in CD74 – ROS1Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITDFGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.Resistant mutations in CML and Ph(+)ALL - role of ponatinib.Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia: Long-Term Patient Care and ManagementCancer stem cells in basic science and in translational oncology: can we translate into clinical application?Identification of small molecules that disrupt signaling between ABL and its positive regulator RIN1A Cell-Based Assay for Measuring Endogenous BcrAbl Kinase Activity and Inhibitor ResistanceImplementing Genome-Driven Oncology.Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion.Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CMLA cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis.Polypharmacology in Precision Oncology: Current Applications and Future ProspectsTargeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia.Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemiasBosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study.Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report.Update: the status of clinical trials with kinase inhibitors in thyroid cancerTyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous LeukemiaThe novel phospholipid mimetic KPC34 is highly active against preclinical models of Philadelphia chromosome positive acute lymphoblastic leukemia.Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia.Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations.A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders.
P2860
Q23923997-C82BD615-BA27-4FBE-A790-7C138E0E4ED4Q24629908-963D8637-D5F2-4187-9C3F-2BE9A2A1F483Q26748769-7467B4D7-419F-452E-B5E1-035269550323Q26749324-6E4819D8-3A38-497D-B2CF-0FB865AE4177Q26766299-91169C86-5CE2-4D17-9BD4-ACFB93C871F9Q26799387-5DEF4A3F-C72B-4B80-866B-53C96E0BDF26Q26849792-281B3594-BCD7-4768-BBE8-CFBEF3265ABBQ27004032-222A92A8-2AAA-4123-84B7-6F8CCF0941E5Q27028181-38267F74-F03A-4981-9C25-808D69B21020Q27612411-8D5C4342-C2BC-46F1-845A-1877A303833CQ27678436-0F98CD0C-3C64-44E3-AFFB-162012F11E38Q27852087-20E4DD33-4E5A-4F2F-A3CD-29DCDFA8F82AQ27852999-6390AAB7-26DD-4F0F-BF23-E0E7EFBDA6ABQ27853085-5A502705-0C48-4F9D-A1F4-DD71949E1B66Q27853298-8F167181-4815-4512-B109-D4E6D7A4EE4CQ28075963-DA0DC8B5-0571-428B-A5D6-1BDEB57B67BBQ28081844-598AD8DC-80C4-4B33-BA9B-E01E9AD29D28Q28545055-51B1ECE3-66B8-4C5E-A46F-CA3A0220D817Q28553892-A73CEFB0-38E4-45D2-AC0B-5036FA3A1092Q30235979-4F1C17B2-921E-4618-A999-95233CFC3E98Q30245010-525EF783-84E5-4CEB-ADD1-24707AD9358BQ30251920-D3E20F8E-AD65-4E75-A9F3-F625491D43F5Q30357188-79E62126-96D4-4EB9-BD81-BC8872317E76Q30396736-9FD89204-EB3E-47FC-A10F-5760210804ACQ30846907-96A85FDF-B3C9-4587-BE62-986BED9DD3E7Q33292152-31E1A392-95F5-415C-8A55-ED80C675450AQ33408546-E7EFCCF2-8113-4B23-AEB2-BACDAAAD9570Q33411250-326EE6C1-8B01-4F25-9395-0A3248902D93Q33412495-38E34521-C0EE-4970-A844-7370F0C68869Q33441382-21089A93-F433-4506-9C08-78E03318FD63Q33442587-1CFA82BC-8253-4B57-ADCC-8FCCEC7137D4Q33570056-97F901C1-C638-40FD-A15C-6512A97A4E35Q33806617-26694251-4B8A-4EA6-9149-5FBE22CF5C18Q33828913-F7C1DCC4-33FF-4AF0-B03D-75E15F382D00Q33903030-6F5C46C3-E5A4-498B-8B3F-D6E0F8A60C26Q34052899-94767461-3434-482F-8723-B9779E5FE119Q34417824-0764DFA4-D947-427E-951E-52970D75578FQ34448958-622425BB-201F-4D1F-ADF8-BE0C780A22D6Q34518436-F6C968C0-5908-4E14-A29D-A15E1D4BE8DDQ34608239-C5851DE0-C5E9-4FBE-9141-50A1A86E0AA2
P2860
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
@ast
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
@en
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
@nl
type
label
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
@ast
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
@en
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
@nl
altLabel
Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
@en
prefLabel
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
@ast
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
@en
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
@nl
P2093
P2860
P50
P3181
P356
P1476
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
@en
P2093
Christopher D Turner
Dale Bixby
Frank G Haluska
Michael J Mauro
Michael W N Deininger
Moshe Talpaz
Narayana I Narasimhan
Neil P Shah
Thomas O'Hare
P2860
P304
P3181
P356
10.1056/NEJMOA1205127
P407
P577
2012-11-29T00:00:00Z